{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T19:20:28Z","timestamp":1784920828617,"version":"3.55.0"},"reference-count":42,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T00:00:00Z","timestamp":1681862400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Deutsche Derma Gesell"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:title>Summary<\/jats:title><jats:sec><jats:title>Background and objectives<\/jats:title><jats:p>Psoriasis is a common skin disorder with a high physical and psychological burden for patients. Up to 30% of the patients are candidates for a systemic treatment. The aim of this study was to describe the characteristics and the real\u2010world systemic treatment of psoriasis patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and methods<\/jats:title><jats:p>This study was based on German medical claims data. A cross\u2010sectional analysis observed all psoriasis patients in 2020. A longitudinal analysis was conducted, addressing psoriasis patients who newly started a systemic treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In total, 116,507 prevalent psoriasis patients and 13,449 newly treated patients were followed. Of all prevalent patients, 15.2% received systemic treatment in 2020 (8.7% systemic corticosteroids). Of the newly treated patients, 95.2% started with conventional treatment (79.2% systemic corticosteroids), 4.0% with biologics and 0.9% with apremilast. The rate of treatment discontinuation\/switch after one year was highest for corticosteroids (91.3%) and lowest for biologics (23.1%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Around 15% of psoriasis patients in Germany received a systemic treatment, with &gt;\u00a050% of these prescribed systemic corticosteroids. Therefore, we conclude that systemic treatment is not in line with guideline recommendations in a substantial number of observed patients. The lowest discontinuation\/switch rates for biologics support their wider use.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ddg.15030","type":"journal-article","created":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T07:47:20Z","timestamp":1681890440000},"page":"611-619","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Real\u2010world systemic treatment of patients with psoriasis: A retrospective study based on German claims data"],"prefix":"10.1111","volume":"21","author":[{"given":"Tanja","family":"Heidbrede","sequence":"first","affiliation":[{"name":"UCB Pharma  Monheim Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antje","family":"Mevius","sequence":"additional","affiliation":[{"name":"IPAM e.V. University of Wismar  Wismar Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Kessel","sequence":"additional","affiliation":[{"name":"UCB Pharma  Monheim Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Wilke","sequence":"additional","affiliation":[{"name":"IPAM e.V. University of Wismar  Wismar Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"Maywald","sequence":"additional","affiliation":[{"name":"AOK PLUS  Dresden Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Thiem","sequence":"additional","affiliation":[{"name":"Clinic and Policlinic for Dermatology and Venereology University Medical Center Rostock  Rostock Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,4,19]]},"reference":[{"key":"e_1_2_8_2_1","unstructured":"AugustinM GlaeskeG Hagenstr\u00f6mK.Psoriasisreport. Pr\u00e4vention Versorgung Innovation.2021. Available from:https:\/\/www.tk.de\/resource\/blob\/2105142\/9fc664ddbfa42f94c3796a2211469f7f\/hautreport\u2010psoriasis\u2010lang\u2010data.pdf. [Last accessed June 14 2022]."},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(99)70112-X"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2230.2001.00832.x"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1590"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.82"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.339"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00105-021-04913-2"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0265741"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3387"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61128-3"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0804595"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-0770"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.0024"},{"issue":"9","key":"e_1_2_8_15_1","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1111\/ddg.13936","article-title":"S2k guidelines for the treatment of psoriasis in children and adolescents \u2013 Short version part 2","volume":"17","author":"Eisert L","year":"2019","journal-title":"J Dtsch Dermatol Ges"},{"issue":"5","key":"e_1_2_8_16_1","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/ddg.13516","article-title":"S3 Guideline for the treatment of psoriasis vulgaris, update \u2013 Short version part 1 \u2013 Systemic treatment","volume":"16","author":"Nast A","year":"2018","journal-title":"J Dtsch Dermatol Ges"},{"issue":"6","key":"e_1_2_8_17_1","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1111\/ddg.14508_g","article-title":"Deutsche S3\u2010Leitlinie zur Therapie der Psoriasis vulgaris, adaptiert von EuroGuiDerm \u2013 Teil 1: Therapieziele und Therapieempfehlungen","volume":"19","author":"Nast A","year":"2021","journal-title":"J Dtsch Dermatol Ges"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14454"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.02.044"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.11.057"},{"issue":"4","key":"e_1_2_8_21_1","first-page":"13","article-title":"Recommendations for initiating systemic therapy in patients with psoriasis","volume":"12","author":"Martin G","year":"2019","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00184-7"},{"key":"e_1_2_8_23_1","unstructured":"HolstiegeJ KlimkeK AkmatovMK et\u00a0al.Bundesweite Verordnungstrends biologischer Arzneimittel bei h\u00e4ufigen Autoimmunerkrankungen 2012 bis 2018. Available from:https:\/\/doi.org\/10.20364\/VA\u201021.03[Last accessed October 25 2022]."},{"key":"e_1_2_8_24_1","article-title":"ATC\u2010Klassifikation mit Tagesdosen f\u00fcr den deutschen Arzneimittelmarkt des GKV\u2010Arzneimittelindex im Jahr 2020","volume":"2020","author":"Fricke U GJ","journal-title":"Wissenschaftliches Institut der AOK (WIdO);"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1159\/000503859"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12895-018-0074-0"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2018.24.7.623"},{"key":"e_1_2_8_28_1","unstructured":"WHO.Guidelines for ATC classification and DDD assignment 2022. Available from:https:\/\/www.whocc.no\/atc_ddd_index_and_guidelines\/guidelines\/[Last accessed October 25 2022]."},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1505557"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.07.023"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2006.07405.x"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1590\/abd1806-4841.20153038"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32549-6"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2013.5264"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.4219"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1159\/000510712"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.2310\/7750.2013.13126"},{"issue":"10","key":"e_1_2_8_38_1","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1111\/j.1610-0387.2011.07713.x","article-title":"Systemic treatment with corticosteroids in psoriasis\u2013health care provision far beyond the S3\u2010guidelines","volume":"9","author":"Augustin M","year":"2011","journal-title":"J Dtsch Dermatol Ges"},{"issue":"3","key":"e_1_2_8_39_1","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/ddg.13464","article-title":"Analysis of pharmaceutical care in patients with psoriatic arthritis using statutory health insurance data","volume":"16","author":"Sondermann W","year":"2018","journal-title":"J Dtsch Dermatol Ges"},{"key":"e_1_2_8_40_1","unstructured":"NastA AmelunxenL AugustinM et\u00a0al.S3\u2010Leitlinie zur Therapie der Psoriasis vulgaris Update 2017.2017(013):1\u2010156."},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00573-1"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2012.755255"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-019-00969-8"}],"container-title":["JDDG: Journal der Deutschen Dermatologischen Gesellschaft"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ddg.15030","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T13:58:22Z","timestamp":1711029502000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ddg.15030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,19]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["10.1111\/ddg.15030"],"URL":"https:\/\/doi.org\/10.1111\/ddg.15030","archive":["Portico"],"relation":{},"ISSN":["1610-0379","1610-0387"],"issn-type":[{"value":"1610-0379","type":"print"},{"value":"1610-0387","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,19]]},"assertion":[{"value":"2022-11-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-19","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}